Osmetech Licenses Warfarin-Dosing SNP From Marshfield Clinic

Nov 02, 2007

NEW YORK (GenomeWeb News) - Osmetech said today it has exclusively licensed a molecular biomarker from Marshfield Clinic, a clinical and research facility in western Wisconsin, that it plans develop into a genetic test for determining appropriate warfarin doses.

Osmetech plans to develop, manufacture, and sell a genetic test based on the biomarker. Osmetech CEO James White said the biomarker will be used on the company’s XT-8 platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

NIH Boost Proposed

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Police, Genealogy, and Privacy

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

Gotta Sequence 'Em All

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

This Week in Science

In Science this week: environmental DNA can help in studies of marine animals, and more.

Main menu